US 12,077,790 B2
Optimized binuclease fusions and methods
James Arthur Posada, St. Petersburg, FL (US); Sanjay Patel, San Diego, CA (US); Weihong Yu, San Diego, CA (US); and Chris Gabel, Seattle, WA (US)
Assigned to Resolve Therapeutics, LLC, Miami, FL (US)
Filed by Resolve Therapeutics, LLC, St. Petersburg, FL (US)
Filed on Dec. 23, 2021, as Appl. No. 17/560,522.
Application 17/560,522 is a continuation of application No. 16/313,656, abandoned, previously published as PCT/US2017/040267, filed on Jun. 30, 2017.
Claims priority of provisional application 62/357,756, filed on Jul. 1, 2016.
Prior Publication US 2022/0112474 A1, Apr. 14, 2022
Int. Cl. C12N 9/22 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/22 (2013.01) [C12Y 301/21001 (2013.01); C12Y 301/27005 (2013.01); A61K 38/00 (2013.01); C07K 2317/72 (2013.01); C07K 2319/30 (2013.01)] 28 Claims
 
1. A polypeptide comprising a first nuclease domain, a second nuclease domain, and an Fc domain, wherein the first nuclease domain is human DNase1 and the second nuclease domain is human RNase1, wherein the human DNase1 is operably linked with or without a linker in tandem from N- to C-terminus to the human RNase1, and wherein the human RNase1 is operably linked with or without a linker to the Fc domain, wherein the polypeptide comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1.